Literature DB >> 20376643

[Treatment of progressive heart failure: pharmacotherapy, resynchronization (CRT), surgery].

Bernhard Maisch1, Sabine Pankuweit.   

Abstract

The treatment of progressive and terminal heart failure follows the principle of causative therapy. Therefore, etiology and pathophysiology of the underlying disease and its hemodynamic conditions are indispensable. This applies to coronary artery disease, hypertension, valvular heart disease, the cardiomyopathies with and without inflammation, and microbial persistence similarly. The classic treatment algorithms both in heart failure with and without reduced ejection fraction are based on measures onloading the heart (angiotensin-converting enzyme inhibitors, angiotensin antagonists, beta-blockers, diuretics) and on antiarrhythmics and anticoagulation, when needed. Device therapy for cardiac resynchronization in left bundle branch block and permanent stimulation therapy may contribute to the hemodynamic benefit. ICD (implantable cardioverter defibrillator) therapy prevents sudden cardiac death, which is often associated with progressive heart failure. Heart transplantation and left ventricular assist devices are final options in the treatment repertoire of terminal heart failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376643     DOI: 10.1007/s00059-010-3329-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  69 in total

1.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

2.  [Cardiology on the edge of the right track].

Authors:  Bernhard Maisch; Helmut Drexler
Journal:  Herz       Date:  2009-03       Impact factor: 1.443

3.  High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity.

Authors:  A Matsumori; H Igata; K Ono; A Iwasaki; T Miyamoto; R Nishio; S Sasayama
Journal:  Jpn Circ J       Date:  1999-12

4.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

5.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Authors:  K Swedberg; M Pfeffer; C Granger; P Held; J McMurray; G Ohlin; B Olofsson; J Ostergren; S Yusuf
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712

6.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

7.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

Review 8.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

9.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

10.  Myocarditis confirmed by biopsy presenting as acute myocardial infarction.

Authors:  M R Costanzo-Nordin; J B O'Connell; R Subramanian; J A Robinson; P J Scanlon
Journal:  Br Heart J       Date:  1985-01
View more
  2 in total

1.  [Renoprotective effect of small volumes of hypertonic saline solution in chronic heart failure patients with marked fluid retention: results of a case-control study].

Authors:  R De Vecchis; A Ciccarelli; C Ariano; A Pucciarelli; C Cioppa; A Giasi; A Fusco; S Cantatrione
Journal:  Herz       Date:  2010-10-28       Impact factor: 1.443

2.  Cardiac stem cell therapy. Registered trials and a pilot study in patients with dilated cardiomyopathy.

Authors:  C Nesselmann; A Kaminski; G Steinhoff
Journal:  Herz       Date:  2011-03       Impact factor: 1.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.